HOME >> BIOLOGY >> NEWS
Shorter tuberculosis therapies could lead to substantial reductions in cases and deaths

Boston, MA -- New, shorter therapies to treat tuberculosis (TB), which kills millions worldwide each year, may make TB control efforts substantially more effective by simplifying treatment, improving patient outcomes and reducing transmission of new infections. Looking at the potential benefits if a two-month regimen becomes available during the next decade, a new study led by researchers at the Harvard School of Public Health (HSPH) reports that as many as 11 million cases and 5 million deaths could be averted through 2030 in the South-East Asia region alone, compared to a situation in which treatment continues at current levels with existing drug regimens. The research appears in the August 2006 online edition of Public Library of Science Medicine (www.plos.org).

Every year, some eight or nine million people develop active TB and some two million people die from the disease. The cornerstone of global control efforts is the World Health Organization's DOTS strategy, which relies on four or more drugs administered under the observation of health care workers for at least six months. No new first-line TB drugs have been developed in over 30 years, but recently an array of promising new drug candidates have been identified, which raises hopes that novel, shorter regimens may enter the TB treatment arsenal in the coming years.

Exploring a number of different scenarios, the researchers developed a mathematical model of TB to study what impact shortening treatment durations might have on the course of the epidemic. The results showed that shorter regimens could produce dramatic benefits at the population level by reducing patients' opportunities to default from treatment and therefore improving their own outcomes as well as curtailing transmission to others. Other possible indirect benefits were explored in alternative scenarios in which new regimens are accompanied by wider case detection, which might arise if sho
'"/>

Contact: Todd Datz
tdatz@hsph.harvard.edu
617-432-3952
Harvard School of Public Health
31-Jul-2006


Page: 1 2

Related biology news :

1. Shorter colds, milder flu may follow from newly revealed immune mechanism
2. Einstein researchers prototype vaccine could provide improved protection against tuberculosis
3. Handicapping tuberculosis may be the way to a better vaccine
4. Developing a more effective vaccine for tuberculosis
5. Why is long-term therapy required to cure tuberculosis?
6. UA researchers identify new adherence factor, Pili, produced by tuberculosis
7. Pitt phage hunter takes on tuberculosis
8. Cost-effectiveness of treating multidrug-resistant tuberculosis
9. New potential drug target in tuberculosis
10. National Institutes of Health funds $13.7 million for Texas tuberculosis study
11. Einstein researchers find potential new drugs for tuberculosis

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/13/2019)... ... March 13, 2019 , ... Leak Detection Associates , the leading global ... Industries, is excited to announce that it will be returning to INTERPHEX ... newly installed and highly experienced management team immediately marked Interphex as the show ...
(Date:3/9/2019)... Calif. (PRWEB) , ... March 07, 2019 , ... ... of a full day workshop presented by University of California Riverside’s EPIC ... held from 8 a.m. to 6 p.m. on Tuesday, March 17, 2019. The location ...
(Date:3/9/2019)... ... March 08, 2019 , ... Ace Laboratories, ... Well-Mints™ resveratrol + ribose hard candy lozenges ( http://www.well-mints.com ). , Well-Mints™ each ... flavored hard candy base dusted with powdered sugar. , Well-Mints'™ patented technology delivers ...
Breaking Biology News(10 mins):
(Date:3/12/2019)... (PRWEB) , ... March 11, 2019 , ... ... first hospital system in Colorado, and among the first in the nation, to ... around lab draws, IV placement and overall degree to which staff showed compassion ...
(Date:3/11/2019)... ... ... In this live webinar, the featured speakers will focus on the many attributes that ... how to use the information they have from the protocol and clinical trial knowledge, ... is properly designed and set up to ensure flawless execution. As clinical trial success ...
(Date:3/9/2019)... SAN DIEGO (PRWEB) , ... March 07, 2019 ... ... Agilent Technologies, is a pioneer in the development and commercialization of high performance, ... and PhysioStim, a leading European CRO with GLP-certified expertise in cardiovascular pharmacology and ...
(Date:3/5/2019)... ... March 05, 2019 , ... San Fransisko, or Sisko ... purchased him at four years old to pursue a career in dressage. According ... the most talented horse that she’d ever worked with. Unfortunately, Sisko suffered an ...
Breaking Biology Technology:
Cached News: